

TELUS Health Enhanced Drug Review process

Webinar

May 1, 2019





Welcome



Vicky Lee,
Clinical Pharmacist



Daria O'Reilly,
Lead Health Economist



Agenda

- The intake process of drug submission materials
- The clinical and economic review procedures
- The timelines for the review process
- How the outcome of the review informs formulary listing decisions and recommendations



Objectives

- Provide clarity around the TELUS Health Enhanced Drug Review process and timelines
- Distinguishing the role of TELUS Health with respect to Carriers within the drug review process


TELUS Health



~12 million
lives covered.




Adjudicate for a wide
range of insurers.



Over 400 formularies
housed on the
TELUS Health System.

The team



TELUS Health Enhanced Drug Review process

Submission

- All submissions are required to be electronic and can be sent through 2 methods:
 - The Central Inbox: drug.submissions@telus.com

OR

- Gateway file share site has been created to help facilitate transfer of files larger than 10MB in size
- We no longer accept submissions mailed in on a USB key



Gateway site

Please reach out through the drug.submissions@telus.com to request to be set up as a user on the Gateway site.

When access is requested, a username will be created and sent via email

- At the time of request, instructions for resetting password and uploading files will be sent



Submission Confirmation

Once all required components are received and submission is deemed complete:

- An email communication will be sent out to confirm that submission is complete and outline review timelines
- An email communication will also be sent requesting missing components




Submission requirements

1. Executive summary
2. Health Canada notice of compliance (if available)
3. Product monograph (English & French)
4. Product summary (MS Excel template)
5. Fact sheet (MS Word template)
6. Pricing
7. Clinical summary
8. Pivotal trial publications
9. Budget impact analysis
 - a) Written report
 - b) Modifiable MS Excel model
10. Economic Evaluation – Pharmacoeconomic analysis (Cost Utility Analysis)
 - a) Written report
 - b) Modifiable MS Excel model
11. References



TELUS Enhanced Drug Review process



Clinical review

Two types of clinical reviews


Abbreviated reviews

- Performed in house at TELUS Health

Extensive reviews

- Performed by the Drug Review External Committee (DREC)
- All DREC members are held under a non-disclosure agreement with TELUS Health

Extensive Clinical Review




Economic review

Budget impact analysis




Economic Evaluation



Drug review overview & timelines

Overall process - timing



Reviews at a glance - 2018

	Total number in 2018
Complete submission received	65
Incomplete submission received	16

*Includes only branded or single source products (generic submissions and approvals have been omitted).



Final steps

Listing decisions

Listing decisions are made to TELUS Health Managed formularies.

1. TELUS Complete formulary
2. National formulary

Changes are made to the formularies after the formulary committee meetings and final decisions are made by the team (~6-9 months from complete submission).



Carrier communication

Decisions for TELUS Health managed formularies are communicated to all carriers on a monthly basis.

Reports and recommendation are provided for Carriers that subscribe to the TELUS Health Enhanced Drug Review

- Carrier(s) processes begin
 - Final decision is left to carrier(s)





Summary

- Provide clarity around the TELUS Health Enhanced Drug Review process and timelines
 - Review Timeline: ~6-9 months
- Distinguishing the role of TELUS Health with respect to Carriers within the drug review process
 - TELUS Health team completes the reviews and makes decisions for TELUS Health Managed formularies
 - Additionally, makes recommendations to Carriers

Questions ?

